The primary objective of the study is to determine the frequency of transmission of viruses carrying at least one antiretroviral resistance mutation in all participants newly diagnosed with HIV-1
Participant (male or female) aged 18 years or older ;
Participant newly diagnosed in the laboratory, for whom mandatory HIV seropositivity reporting to Santé Publique France (SPF) is required ;
Participant naïve to all antiretroviral treatments (except PrEP and/or post-exposure prophylaxis [PEP]) ;
Participant with an available HIV resistance genotype, including amplification of at least reverse transcriptase and protease ;
Participant who objects to the use of their data ;
Participant currently on antiretroviral treatment ;
Participant subject to legal protection measures (safeguard of justice).